Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

  title={Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome},
  author={Orrin Devinsky and Anup D. Patel and Helen J Cross and Vicente Villanueva and Elaine C. Wirrell and Michael D Privitera and Sam Greenwood and Claire Roberts and Daniel Checketts and Kevan E. VanLandingham and Sameer M. Zuberi},
  journal={The New England Journal of Medicine},
Background Cannabidiol has been used for treatment‐resistant seizures in patients with severe early‐onset epilepsy. [] Key Method Methods In this double‐blind, placebo‐controlled trial conducted at 30 clinical centers, we randomly assigned patients with the Lennox–Gastaut syndrome (age range, 2 to 55 years) who had had two or more drop seizures per week during a 28‐day baseline period to receive cannabidiol oral solution at a dose of either 20 mg per kilogram of body weight (20‐mg cannabidiol group) or 10 mg…

Figures and Tables from this paper

Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea

In this first Korean study, CBD was safe and tolerable for use and could be expected to potentially reduce the seizure frequency in pediatric patients with Lennox-Gastaut syndrome or Dravet syndrome.

Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox–Gastaut Syndrome: A Systematic Review and Meta-Analysis

Adjunctive CBD resulted in a greater reduction in seizure frequency and a higher rate of AEs than placebo in patients with LGS presenting seizures uncontrolled by concomitant AEDs.

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex

Both cannabidiol dosages were equally efficacious in reducing tuberous sclerosis complex–associated seizures compared with placebo, but the smaller dosage led to fewer adverse events.

Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex

This systematic review with meta-analysis supports the use of CBD in the treatment of patients with seizures, originated in DS, LGS, and TSC, who are resistant to the common medications, presenting satisfactory benefits in reducing seizures and tolerable toxicity.

Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy

Efficacy and tolerance in the study of synthetic CBD treatment in pharmacoresistant epilepsy is similar to open label studies using plant derived CBD, which might be a reasonable alternative to plant derived cannabidiol.

Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy

Efficacy, safety and tolerability of CBD treatment were assessed through the evaluation of seizure frequency and reports of adverse effects, and data suggest that CBD may have beneficial effects in patients with DEE and an acceptable safety profile.

Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome

Cannabidiol does not appear to be a cost-effective therapeutic option in LGS patients at a willingness-to-pay threshold of $150,000/QALY, and results from the 5000-simulation probabilistic sensitivity analysis indicated a 0% chance of CBD being cost effective at a $150%, with a 95% credible range for the incremental cost-effectiveness ratio.

Cannabidiol Treatment for Lennox-Gastaut Syndrome at a Single Tertiary Center in South Korea

CBD could be a treatment option for children and young adults with drug-resistant LGS with a tolerable safety profile and age at epilepsy onset (>3 years) was associated with a favorable response to CBD treatment.

Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial.

CBD transdermal gel was safe, well tolerated, and was associated with reductions in FIAS and TCS frequency and disease burden in children with DEEs in Australia and New Zealand.



Experience in the use of clobazam in the treatment of Lennox–Gastaut syndrome

Clobazam appears to have a safe profile and sustained effectiveness over the first 3 years of use in LGS and other epilepsy syndromes with intractable seizures, which makes it a viable long-term treatment option.

Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome

This study provides Class II evidence that clobazam as adjunctive therapy is efficacious, in a dosage-dependent manner, in reducing mean weekly drop seizure rates of patients with LGS over 12 weeks.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

This study provides Class I evidence that for children with Dravet syndrome, CBD resulted in more AEs than placebo but was generally well-tolerated.

Definition and natural history of Lennox‐Gastaut syndrome

Lennox‐Gastaut syndrome (LGS) is a rare epileptic encephalopathy with a peak age of onset of 3–5 years of age. Reported prevalence rates for LGS vary widely from 1–10% of all childhood epilepsies.

Conclusions: Long‐term management of Lennox‐Gastaut syndrome: Future directions

A defined strategy for transitioning patients from pediatric to adult care should be an essential component of the long-term management plan for Lennox-Gastaut syndrome.

Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open‐label clinical study with cannabidiol

The results suggest that CBD may have beneficial effects on patient QOL, distinct from its seizure‐reducing effects; however, further studies in placebo‐controlled, double‐blind trials are necessary to confirm this finding.

Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy

Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children, and it is predicted a drug–drug interaction.